Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019
Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019
SUMMARY
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Alpha-2C adrenergic receptor or ADRA2C is an alpha-2 adrenergic receptor. It mediates the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. This receptor plays a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system.
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 1 respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Schizophrenia, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Cognitive Disorders, Dementia Associated With Alzheimer's Disease, Depression, Generalized Anxiety Disorder (GAD), Major Depressive Disorder, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Pervasive Developmental Disorder (PDD), Post-Traumatic Stress Disorder (PTSD) and Psychiatric Disorders.
The latest report Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Alpha-2C adrenergic receptor or ADRA2C is an alpha-2 adrenergic receptor. It mediates the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. This receptor plays a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system.
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 1 respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Schizophrenia, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Cognitive Disorders, Dementia Associated With Alzheimer's Disease, Depression, Generalized Anxiety Disorder (GAD), Major Depressive Disorder, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Pervasive Developmental Disorder (PDD), Post-Traumatic Stress Disorder (PTSD) and Psychiatric Disorders.
The latest report Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C)
- The report reviews Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Overview
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Companies Involved in Therapeutics Development
Avineuro Pharmaceuticals Inc
Bayer AG
Denovo Biopharma LLC
Otsuka Holdings Co Ltd
SK Biopharmaceuticals Co Ltd
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Drug Profiles
AVN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexpiprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexpiprazole LAI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DB-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadaltran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-PSY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Dormant Products
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Discontinued Products
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Product Development Milestones
Featured News & Press Releases
Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder
Feb 22, 2019: Health Canada approves Otsuka and Lundbeck’s REXULTI (brexpiprazole) as Adjunctive treatment of Major Depressive Disorder
Feb 14, 2019: Lundbeck and Otsuka report phase III data evaluating Brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
Dec 21, 2018: European launch of Rexulti (brexpiprazole) commences in Switzerland
Nov 30, 2018: Otsuka and Lundbeck report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
Oct 29, 2018: Otsuka and Lundbeck report positive brexpiprazole results
Jul 31, 2018: Lundbeck and Otsuka’s Rxulti (brexpiprazole) approved by the European Commission
Jun 01, 2018: Lundbeck and Otsuka's Rxulti (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults
May 24, 2018: Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
Apr 18, 2018: REXULTI Tablets, a New Antipsychotic Drug, Launched in Japan
Jan 19, 2018: Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti Tablets for Schizophrenia
Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101
Nov 01, 2017: Lundbeck and Otsuka will initiate a third phase III trial to evaluate the use of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type
Oct 12, 2017: Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder
Sep 13, 2017: Otsuka and Lundbeck To Present Data On brexpiprazole at upcoming Psych Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Overview
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Companies Involved in Therapeutics Development
Avineuro Pharmaceuticals Inc
Bayer AG
Denovo Biopharma LLC
Otsuka Holdings Co Ltd
SK Biopharmaceuticals Co Ltd
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Drug Profiles
AVN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexpiprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexpiprazole LAI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DB-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fadaltran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-PSY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Dormant Products
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Discontinued Products
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Product Development Milestones
Featured News & Press Releases
Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder
Feb 22, 2019: Health Canada approves Otsuka and Lundbeck’s REXULTI (brexpiprazole) as Adjunctive treatment of Major Depressive Disorder
Feb 14, 2019: Lundbeck and Otsuka report phase III data evaluating Brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
Dec 21, 2018: European launch of Rexulti (brexpiprazole) commences in Switzerland
Nov 30, 2018: Otsuka and Lundbeck report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
Oct 29, 2018: Otsuka and Lundbeck report positive brexpiprazole results
Jul 31, 2018: Lundbeck and Otsuka’s Rxulti (brexpiprazole) approved by the European Commission
Jun 01, 2018: Lundbeck and Otsuka's Rxulti (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults
May 24, 2018: Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
Apr 18, 2018: REXULTI Tablets, a New Antipsychotic Drug, Launched in Japan
Jan 19, 2018: Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti Tablets for Schizophrenia
Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101
Nov 01, 2017: Lundbeck and Otsuka will initiate a third phase III trial to evaluate the use of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type
Oct 12, 2017: Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder
Sep 13, 2017: Otsuka and Lundbeck To Present Data On brexpiprazole at upcoming Psych Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Avineuro Pharmaceuticals Inc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Denovo Biopharma LLC, H2 2019
Pipeline by Otsuka Holdings Co Ltd, H2 2019
Pipeline by SK Biopharmaceuticals Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Avineuro Pharmaceuticals Inc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Denovo Biopharma LLC, H2 2019
Pipeline by Otsuka Holdings Co Ltd, H2 2019
Pipeline by SK Biopharmaceuticals Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Avineuro Pharmaceuticals Inc
Bayer AG
Denovo Biopharma LLC
Otsuka Holdings Co Ltd
SK Biopharmaceuticals Co Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
Avineuro Pharmaceuticals Inc
Bayer AG
Denovo Biopharma LLC
Otsuka Holdings Co Ltd
SK Biopharmaceuticals Co Ltd
